VE RAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced a collaboration with Ardigen S.A., an AI-driven computational partner for modern ...
Ardigen’s AI and computational biology capabilities will strengthen VERAXA’s in-house AI efforts to optimize cancer target pair selection for conditionally active T cell engagers and antibody-drug ...
VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced a collaboration with Ardigen S.A., an AI-driven ...
Ardigen platform supports VERAXA's in-house AI capabilities to optimize cancer target pair selection for conditionally active t cell engagers (TCEs) and antibody drug conjugates (ADCs)ZURICH, SWITZERL ...
I would like to receive updates and special offers from Dow Jones and affiliates. I can unsubscribe at any time.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results